Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK2141795 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Stage 1 | EXPERIMENTAL | Three to six patients on a medium dose of GSK2141795 for four weeks |
| Stage 2 | EXPERIMENTAL | Nine to eighteen subjects on a low, medium or high dose of GSK2141795 for four weeks |
| GSK2141795 | EXPERIMENTAL | Oral GSK214179 given daily to patients with cancer. Groups of approximately three patients will receive GSK2141795 at increasing doses until a maximum tolerated dose is identified. |
| Name | Type | Description |
|---|---|---|
| GSK2141795 | DRUG | GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models |
Inclusion Criteria: 1. Capable of giving written informed consent 2. Females of non-childbearing potential, 18 years or older with ovarian cancer 3. Histologically or cytologically confirmed diagnosis of PET-positive recurrent or persistent ovarian cancer 4. Histologically or cytologically confirme...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
GSK2141795 is an investigational small molecule being developed by GSK plc for the treatment of cancer, including solid tumours. It is currently in Phase 1 clinical development and is not approved by the FDA. The drug has been studied in patients with various types of cancer to evaluate its safety and pharmacokinetics.
GSK2141795 is an oral AKT inhibitor. It works by targeting the AKT protein, which is part of the PI3K/AKT signaling pathway often involved in cancer cell growth and survival. By inhibiting AKT, the drug aims to block this pathway and potentially slow or stop tumour growth.
GSK2141795 is developed by GSK plc, a global pharmaceutical company listed on the London Stock Exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and effectiveness in treating cancer.
GSK2141795 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities such as the FDA. The Phase 1 trials are designed to assess the drug's safety, tolerability, and pharmacokinetics in patients with cancer.
GSK2141795 has been studied in two completed Phase 1 clinical trials. The first, NCT00920257, was a first-time-in-human study in patients with cancer. The second, NCT01266954, investigated the drug's pharmacokinetics and pharmacodynamics in women with ovarian cancer using FDG PET imaging.
Yes, GSK2141795 is an AKT inhibitor. It is a small molecule designed to inhibit the AKT protein, which plays a role in cancer cell survival and proliferation. The drug is being studied as a potential treatment for solid tumours and other cancers.